References
- Mussetti A, Dalto S, Montefusco V. Effective treatment of pomalidomide in central nervous system myelomatosis. Leuk Lymphoma 2013;54;864–866.
- Cerase A, Tarantino A, Gozzetti A, . Intracranial involvement in plasmacytomas and multiple myeloma: a pictorial essay. Neuroradiology 2008;50:665–674.
- Lopes da Silva R, Costa I, Prata M, . Plasma cell meningitis: a rare neurological complication of multiple myeloma requiring a high index of suspicion. Acta Neurol Taiwan 2011;20:209–212.
- Licci S, Narciso P. Myelomatous meningitis. Eur J Haematol 2008;81:328.
- Chamberlain MC, Glantz M. Myelomatous meningitis. Cancer 2008;112:1562–1567.
- Savage DG, Mears JG, Balmaceda C, . Leptomeningeal relapse of multiple myeloma following allogeneic stem cell transplantation. Leuk Res 2002;26:689–692.
- Lacy MQ, Hayman SR, Gertz MA, . Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009;27:5008–5014.
- Lacy MQ, Hayman SR, Gertz MA, . Pomalidomide (CC4047) plus low dose dexamethasone (pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010; 24:1934–1939.
- Short KD, Rajkumar SV, Larson D, . Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 2011;25:906–908.
- Lacy MQ, Allred JB, Gertz MA, . Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011;118:2970–2975.